loading

Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten

Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings) - Precision BioSciences (NAS - Benzinga

pulisher
Benzinga

Objective long/short (DTIL) Report - Stock Traders Daily

pulisher
Stock Traders Daily

DTIL Stock Earnings: Precision BioSciences Beats EPS, Beats Revenue for Q1 2024 - MSN

pulisher
MSN

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update - Business Wire

pulisher
Business Wire

Precision BioSciences: Q1 Earnings Snapshot - Houston Chronicle

pulisher
Houston Chronicle

Critical Survey: Precision BioSciences (NASDAQ:DTIL) and Revolution Medicines (NASDAQ:RVMD) - Defense World

pulisher
Defense World

Precision BioSciences (DTIL) to Release Earnings on Monday - Defense World

pulisher
Defense World

Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates

pulisher
Zacks Investment Research

Precision BioSciences announces private stock sale to leadership team - Investing.com Canada

pulisher
Investing.com Canada

Precision BioSciences announces private stock sale to leadership team - Investing.com India

pulisher
Investing.com India

Precision BioSciences (DTIL) Scheduled to Post Quarterly Earnings on Monday - MarketBeat

pulisher
MarketBeat

Precision BioSciences announces private stock sale to leadership team - Investing.com South Africa

pulisher
Investing.com South Africa

Precision BioSciences announces private stock sale to leadership team - Investing.com

pulisher
Investing.com

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300000 in a Private ... - Business Wire

pulisher
Business Wire

Precision BioSciences partner iECURE gains FDA Fast Track status - Investing.com Canada

pulisher
Investing.com Canada

Precision BioSciences partner iECURE gains FDA Fast Track status - Investing.com India

pulisher
Investing.com India

Precision BioSciences partner iECURE gains FDA Fast Track status - Investing.com

pulisher
Investing.com

Precision BioSciences (DTIL) Scheduled to Post Quarterly Earnings on Monday - MarketBeat

pulisher
MarketBeat

Precision BioSciences partner iECURE gains FDA Fast Track status By Investing.com - Investing.com UK

pulisher
Investing.com UK

Precision BioSciences Gets FDA Fast Track Designation for Program to Treat Genetic Urea Cycle Disorder in Newborns - MarketWatch

pulisher
MarketWatch

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the ... - Business Wire

pulisher
Business Wire

This Precision BioSciences Insider Increased Their Holding By 38% Last Year - Yahoo Movies Canada

pulisher
Yahoo Movies Canada

Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies Canada

pulisher
Yahoo Movies Canada

Insider Selling: Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Sells 1,526 Shares of Stock - MarketBeat

pulisher
MarketBeat

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the ... - Yahoo Finance

pulisher
Yahoo Finance

Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?

pulisher
Zacks Investment Research

Precision BioSciences Faces Partnership Termination, Eyes Future - TipRanks.com - TipRanks

pulisher
TipRanks

Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?

pulisher
Zacks Investment Research

Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know

pulisher
Zacks Investment Research

Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?

pulisher
Zacks Investment Research

Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock? - Zacks Investment Research

pulisher
Zacks Investment Research

Octave Bioscience Accelerates Leadership in Precision Care for Neurodegenerative Diseases with Addition of World ... - Business Wire

pulisher
Business Wire

Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates

pulisher
Zacks Investment Research

Precision BioSciences: Q4 Earnings Snapshot - Quartz

pulisher
Quartz

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates

pulisher
Zacks Investment Research

Precision BioSciences stock target raised to $30 on gene editing prospects - Investing.com

pulisher
Investing.com

Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary ... - Business Wire

pulisher
Business Wire

Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates

pulisher
Zacks Investment Research

Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase of Growth - Yahoo Finance

pulisher
Yahoo Finance

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS ... - Business Wire

pulisher
Business Wire

Precision Bio raising $37 million from investors - Business North Carolina

pulisher
Business North Carolina

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

pulisher
Benzinga

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants - Business Wire

pulisher
Business Wire

Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants - Business Wire

pulisher
Business Wire

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates

pulisher
Zacks Investment Research

Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?

pulisher
Zacks Investment Research

Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength? - Yahoo Finance

pulisher
Yahoo Finance

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences - Business Wire

pulisher
Business Wire

Precision Biosciences advances PBGENE-HBV toward clinic - BioWorld Online

pulisher
BioWorld Online

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical ... - Yahoo Finance

pulisher
Yahoo Finance
$77.25
price down icon 3.91%
$151.06
price up icon 2.65%
$29.73
price down icon 1.64%
$170.09
price up icon 3.15%
$376.19
price down icon 0.45%
$92.78
price up icon 0.63%
Kapitalisierung:     |  Volumen (24h):